Transport of desglycinamide-arginine vasopressin across the blood-brain barrier in rats as evaluated by the unit impulse response methodology
- PMID: 2339105
- DOI: 10.1023/a:1015838532048
Transport of desglycinamide-arginine vasopressin across the blood-brain barrier in rats as evaluated by the unit impulse response methodology
Abstract
The pharmacokinetic characteristics of desglycinamide-arginine vasopressin (DGAVP) with respect to its transport across the blood-brain barrier (BBB) were studied with the use of serial CSF sampling in an individual animal and the unit impulse response methodology. Transport rate is determined as BBB clearance, the volume of plasma per unit time cleared of the peptide by BBB transport, and the extent of transport as the percentage of the administered dose transported into the central nervous system. Plasma kinetics of DGAVP were shown to be linear within the dose range studied (50-150 micrograms), plasma mean residence time (MRT) being 18 +/- 4 min (mean +/- SE; n = 9). Elimination of DGAVP from CSF after icv administration was linear, with an MRT of 10 +/- 1 min (n = 9). After iv administration of 100 micrograms DGAVP, CSF concentrations were detectable for 90 min. Transport from plasma to the central nervous system was linear. The BBB transport clearance value was 1.0 +/- 0.3 microliters/min, and 0.026 +/- 0.007% of the administered dose was transported into the central nervous system. Results demonstrate that, within the concentration range studied, DGAVP is transported across the BBB by passive diffusion, although to a very low extent.
Similar articles
-
Penetration of DGAVP (Org 5667) across the blood-brain barrier in human subjects.Peptides. 1987 Mar-Apr;8(2):261-5. doi: 10.1016/0196-9781(87)90101-x. Peptides. 1987. PMID: 3588346
-
Radioimmunoassay of desglycinamide-arginine vasopressin and its application in a pharmacokinetic study in the rat.Peptides. 1988 May-Jun;9(3):555-9. doi: 10.1016/0196-9781(88)90163-5. Peptides. 1988. PMID: 3420013
-
Blood-cerebrospinal fluid barrier to arginine-vasopressin, desmopressin and desglycinamide arginine-vasopressin in the dog.J Endocrinol. 1982 Jun;93(3):319-25. doi: 10.1677/joe.0.0930319. J Endocrinol. 1982. PMID: 7086325
-
[Functional activity of vasopressin analog desglycinamide-arginine-vasopressin].Izv Akad Nauk Ser Biol. 2006 May-Jun;(3):297-305. Izv Akad Nauk Ser Biol. 2006. PMID: 16771143 Review. Russian.
-
[Kinetic analysis of the disposition of hydrophilic drugs in the central nervous system (CNS): prediction of the CNS disposition from the transport properties in the blood-brain and blood-cerebrospinal fluid barriers].Yakugaku Zasshi. 1994 Dec;114(12):950-71. doi: 10.1248/yakushi1947.114.12_950. Yakugaku Zasshi. 1994. PMID: 7869236 Review. Japanese.
Cited by
-
Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models.J Pharmacokinet Pharmacodyn. 2015 Oct;42(5):447-62. doi: 10.1007/s10928-015-9437-x. Epub 2015 Aug 30. J Pharmacokinet Pharmacodyn. 2015. PMID: 26319673 Free PMC article.
-
Effects of proteolytic enzyme inhibitors on the nasal absorption of vasopressin and an analogue.Pharm Res. 1991 Sep;8(9):1175-9. doi: 10.1023/a:1015862603939. Pharm Res. 1991. PMID: 1724082
-
Drug transport across the blood-brain barrier. III. Mechanisms and methods to improve drug delivery to the central nervous system.Pharm World Sci. 1993 Feb 19;15(1):2-9. doi: 10.1007/BF02116163. Pharm World Sci. 1993. PMID: 8485503 Review.
-
Effects of protease inhibitors on vasopressin transport across rat alveolar epithelial cell monolayers.Pharm Res. 1994 Nov;11(11):1617-22. doi: 10.1023/a:1018918022865. Pharm Res. 1994. PMID: 7870680
-
Delivering peptides to the central nervous system: dilemmas and strategies.Pharm Res. 1991 Nov;8(11):1345-50. doi: 10.1023/a:1015884603456. Pharm Res. 1991. PMID: 1798668 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources